Showing results (31-40 of 886) with videos related to

Sort By:
Pageof 89
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|May 1, 1990
Effect of combined androgen blockade with an LHRH agonist and flutamide in one severe case of male exhibitionismL Rousseau, M Couture, A Dupont, et al.
Journal of Steroid Biochemistry|December 1, 1987
Effects of flutamide and aminoglutethimide on plasma 5 alpha-reduced steroid glucuronide concentrations in castrated patients with cancer of the prostateM Brochu, A Bélanger, A Dupont, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|October 1, 1988
Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinomaA Bélanger, F Labrie, A Dupont, et al.
British Medical Journal (Clinical Research Ed.)|August 10, 1985
Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrationsF Labrie, A Dupont, A Belanger, et al.
Cancer|February 1, 1993
Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapyF Labrie, A Belanger, J Simard, et al.
The Journal of Urology|September 1, 1993
Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapyA Dupont, J L Gomez, L Cusan, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|December 1, 1993
Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancerF Labrie, A Dupont, L Cusan, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 1977
Beta-endorphin: stimulation of growth hormone release in vivoA Dupont, L Cusan, M Garon, et al.
European Urology|January 1, 1993
Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancerF Labrie, A Dupont, J Simard, et al.
The Prostate|January 1, 1988
Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamideA Bélanger, M Giasson, J Couture, et al.
Pageof 89